TC-6987 for the Treatment of Mild to Moderate Asthma
Primary Purpose
Asthma
Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
TC-6987
Placebo
Sponsored by

About this trial
This is an interventional treatment trial for Asthma focused on measuring Asthma, Mild to Moderate Asthma
Eligibility Criteria
Inclusion Criteria:
- A clinical diagnosis of persistent mild to moderate asthma requiring at least 3 months of daily treatment with inhaled corticosteroids (ICS).
- A FEV1 value at Screening that is 60-90% of predicted FEV1.
- Age 18 to 65, males or females.
Exclusion Criteria:
- Diagnosis or presence of other pulmonary diseases including chronic obstructive pulmonary disease (COPD) and emphysema.
- Previous life-threatening asthma, such as asthma requiring intubation or ICU admission for asthma.
- Prolonged hospitalization for asthma within the past year (emergency room treatments using nebulized beta-agonists is permitted).
- Not able and willing to stop the use of long-acting beta-agonists (LABAs), cromolyn sodium, methylxanthines, anticholinergic agents, leukotriene inhibitors, or any other non-ICS or non-SABA prescription or over-the-counter anti-asthma medication, including antihistamines, during Screening and during the Study.
- Use of moderate to strong cytochrome P450 3A4 (CYP3A4) inhibitors.
- Use of oral steroids within the last 1 month, or use of >/= 3 steroid bursts in the last 12 months.
- History of upper respiratory tract infection (URI) requiring treatment during the last month prior to Screening.
- Tobacco use within 3 months prior to Screening, or > 5 pack-year lifetime tobacco use.
- Use of smoking cessation therapy within 3 months prior to Screening.
- Uncontrolled Gastroesophageal reflux disease (GERD). Subjects on a stable dose of non-prescription or prescription medications who have been symptom free for 4 wks prior to screening are eligible.
- History within past 6 months of alcohol abuse or illicit drug abuse.
- Myocardial infarction within 12 months prior to Screening.
- Known hypothyroidism, vitamin B12, or folic acid deficiency.
- Known systemic infection (HBV, HCV, HIV, TB).
- FSH level of < 35 IU/L and a LH level < 25 IU/L.
- Urine cotinine level > 50 ng/ml.
- Body Mass Index (BMI) <15 and >35.
- Participation in another clinical trial in the past 3 months.
Sites / Locations
- Clinical research Center of Alabama
- Medical Research of Arizona
- California Allergy and Asthma Medical Group, Inc.
- California Allergy & Asthma Medical Group
- Waterbury Pulmonary Associates
- Avail Clinical Research LLC
- Sarasota Clinical Research
- Florida Pulmonary Research Institute, Inc.
- Allergy Partners of Western North Carolina
- Toledo Center for Clinical Research
- Allergy & Asthma Clinical Research Center
- Clinical Research Institute of Southern Oregon, PC
- Altoona Lung Specialists
- Allergy & Asthma Research of New Jersey, Inc.
- Spartanburg Medical Research
- Pioneer Research Solutions
- Paragon Research
- Utah Clinical Trials, LLC
- VA Adult & Pediatric Allergy & Asthma PC
- Pulmornary Consultants, PLLC
- Medical College of Wisconsin
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
TC-6987
Placebo
Arm Description
Outcomes
Primary Outcome Measures
Change in FEV1 status on Day 28 compared to baseline as a function of treatment (TC-6987 versus placebo)
Co-primary efficacy endpoints:
the change in FEV1 from pre dose on Day 1 to pre dose on Day 28
the change in FEV1 from pre dose on Day 1 to 2 h post dose on Day 28
Secondary Outcome Measures
Number of Asthma Control Days
Number of Asthma Control Days from 14 days prior to Day 1, compared to the 14 days prior to Day 28, as a function of Treatment
Decrease in FEV1 after methacholine dose as a function of treatment
Percentage of patients in which methacholine dose decreases FEV1 by 20% (PC20) at Day 29 compared to Day -1
Number of Asthma Control Days
Number of Asthma Control Days from 14 days prior to Day 1, compared to the 14 days prior to Day 28, as a function of Treatment
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01296087
Brief Title
TC-6987 for the Treatment of Mild to Moderate Asthma
Official Title
A Phase II Multicenter, Randomized, Double-Blind,Parallel Group, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetic Parameters of TC-6987 in Subjects With Persistent Mild to Moderate Asthma
Study Type
Interventional
2. Study Status
Record Verification Date
July 2012
Overall Recruitment Status
Completed
Study Start Date
February 2011 (undefined)
Primary Completion Date
January 2012 (Actual)
Study Completion Date
January 2012 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Targacept Inc.
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study is designed to determine whether TC-6987 improves respiratory function in subjects with asthma by reducing airway hyper-responsiveness and inflammation.
Detailed Description
Asthma is a common, chronic inflammatory disorder of the airways that affects an estimated 20 to 22 million people in the United States. It is characterized by variable and recurring symptoms, notably airflow obstruction, bronchial hyperresponsiveness, and an underlying inflammation. The bronchospasm is caused by inflammation of the muscles surrounding the air passageways, making them smaller, thus more difficult for air to freely move in and out of the lungs. Cardinal symptoms of asthma include coughing, chest tightness, shortness of breath and wheezing. These symptoms are often more severe in the morning and late night, and usually reversible with medications. Clinically, asthma is typically classified according to the frequency of symptoms, forced expiratory volume in 1 second (FEV1), and peak expiratory flow rate.
The rationale for this Phase II proof of concept study is to demonstrate that TC-6987 improves respiratory function in subjects with asthma, compared to placebo, as measured by the Baseline FEV1 on Day 1 compared to the End-of-Treatment FEV1 on Day 28 or Early Withdrawal (EW); and also to assess the safety and tolerability profile of TC-6987 in subjects with asthma.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma
Keywords
Asthma, Mild to Moderate Asthma
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
203 (Actual)
8. Arms, Groups, and Interventions
Arm Title
TC-6987
Arm Type
Experimental
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
TC-6987
Intervention Description
TC-6987 50 mg capsule given once daily on Days 1 to 28
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Matching placebo capsule given once daily on Days 1 to 28
Primary Outcome Measure Information:
Title
Change in FEV1 status on Day 28 compared to baseline as a function of treatment (TC-6987 versus placebo)
Description
Co-primary efficacy endpoints:
the change in FEV1 from pre dose on Day 1 to pre dose on Day 28
the change in FEV1 from pre dose on Day 1 to 2 h post dose on Day 28
Time Frame
Day 28
Secondary Outcome Measure Information:
Title
Number of Asthma Control Days
Description
Number of Asthma Control Days from 14 days prior to Day 1, compared to the 14 days prior to Day 28, as a function of Treatment
Time Frame
Day 1
Title
Decrease in FEV1 after methacholine dose as a function of treatment
Description
Percentage of patients in which methacholine dose decreases FEV1 by 20% (PC20) at Day 29 compared to Day -1
Time Frame
Day 29
Title
Number of Asthma Control Days
Description
Number of Asthma Control Days from 14 days prior to Day 1, compared to the 14 days prior to Day 28, as a function of Treatment
Time Frame
Day 28
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
A clinical diagnosis of persistent mild to moderate asthma requiring at least 3 months of daily treatment with inhaled corticosteroids (ICS).
A FEV1 value at Screening that is 60-90% of predicted FEV1.
Age 18 to 65, males or females.
Exclusion Criteria:
Diagnosis or presence of other pulmonary diseases including chronic obstructive pulmonary disease (COPD) and emphysema.
Previous life-threatening asthma, such as asthma requiring intubation or ICU admission for asthma.
Prolonged hospitalization for asthma within the past year (emergency room treatments using nebulized beta-agonists is permitted).
Not able and willing to stop the use of long-acting beta-agonists (LABAs), cromolyn sodium, methylxanthines, anticholinergic agents, leukotriene inhibitors, or any other non-ICS or non-SABA prescription or over-the-counter anti-asthma medication, including antihistamines, during Screening and during the Study.
Use of moderate to strong cytochrome P450 3A4 (CYP3A4) inhibitors.
Use of oral steroids within the last 1 month, or use of >/= 3 steroid bursts in the last 12 months.
History of upper respiratory tract infection (URI) requiring treatment during the last month prior to Screening.
Tobacco use within 3 months prior to Screening, or > 5 pack-year lifetime tobacco use.
Use of smoking cessation therapy within 3 months prior to Screening.
Uncontrolled Gastroesophageal reflux disease (GERD). Subjects on a stable dose of non-prescription or prescription medications who have been symptom free for 4 wks prior to screening are eligible.
History within past 6 months of alcohol abuse or illicit drug abuse.
Myocardial infarction within 12 months prior to Screening.
Known hypothyroidism, vitamin B12, or folic acid deficiency.
Known systemic infection (HBV, HCV, HIV, TB).
FSH level of < 35 IU/L and a LH level < 25 IU/L.
Urine cotinine level > 50 ng/ml.
Body Mass Index (BMI) <15 and >35.
Participation in another clinical trial in the past 3 months.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
John Winder, MD
Organizational Affiliation
Toledo Center for Clinical Research
Official's Role
Principal Investigator
Facility Information:
Facility Name
Clinical research Center of Alabama
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35209
Country
United States
Facility Name
Medical Research of Arizona
City
Scottsdale
State/Province
Arizona
ZIP/Postal Code
85251
Country
United States
Facility Name
California Allergy and Asthma Medical Group, Inc.
City
Los Angeles
State/Province
California
ZIP/Postal Code
90025
Country
United States
Facility Name
California Allergy & Asthma Medical Group
City
Palmdale
State/Province
California
ZIP/Postal Code
93551
Country
United States
Facility Name
Waterbury Pulmonary Associates
City
Waterbury
State/Province
Connecticut
ZIP/Postal Code
06708
Country
United States
Facility Name
Avail Clinical Research LLC
City
DeLand
State/Province
Florida
ZIP/Postal Code
32720
Country
United States
Facility Name
Sarasota Clinical Research
City
Sarasota
State/Province
Florida
ZIP/Postal Code
34233
Country
United States
Facility Name
Florida Pulmonary Research Institute, Inc.
City
Winter Park
State/Province
Florida
ZIP/Postal Code
32789
Country
United States
Facility Name
Allergy Partners of Western North Carolina
City
Asheville
State/Province
North Carolina
ZIP/Postal Code
28801
Country
United States
Facility Name
Toledo Center for Clinical Research
City
Sylvania
State/Province
Ohio
ZIP/Postal Code
43560
Country
United States
Facility Name
Allergy & Asthma Clinical Research Center
City
Oklahoma City
State/Province
Oklahoma
ZIP/Postal Code
73120
Country
United States
Facility Name
Clinical Research Institute of Southern Oregon, PC
City
Medford
State/Province
Oregon
ZIP/Postal Code
97504
Country
United States
Facility Name
Altoona Lung Specialists
City
Altoona
State/Province
Pennsylvania
ZIP/Postal Code
19115
Country
United States
Facility Name
Allergy & Asthma Research of New Jersey, Inc.
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19115
Country
United States
Facility Name
Spartanburg Medical Research
City
Spartanburg
State/Province
South Carolina
ZIP/Postal Code
29303
Country
United States
Facility Name
Pioneer Research Solutions
City
Houston
State/Province
Texas
ZIP/Postal Code
77036
Country
United States
Facility Name
Paragon Research
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78205
Country
United States
Facility Name
Utah Clinical Trials, LLC
City
Salt Lake City
State/Province
Utah
ZIP/Postal Code
84107
Country
United States
Facility Name
VA Adult & Pediatric Allergy & Asthma PC
City
Richmond
State/Province
Virginia
ZIP/Postal Code
23229
Country
United States
Facility Name
Pulmornary Consultants, PLLC
City
Tacoma
State/Province
Washington
ZIP/Postal Code
98405
Country
United States
Facility Name
Medical College of Wisconsin
City
Milwaukee
State/Province
Wisconsin
ZIP/Postal Code
53226
Country
United States
12. IPD Sharing Statement
Learn more about this trial
TC-6987 for the Treatment of Mild to Moderate Asthma
We'll reach out to this number within 24 hrs